IMPROVEMENTS IN PRODUCTION OF PROTEINS IN HOST CELLS

Abstract: Method of increasing protein production in a host cell where the nucleic acid encoding the protein has an A and/or T rich region in an exon. The method comprising lowering the amount of A and/or T rich region and transfecting a host cell with the altered nucleic acid and obtaining expression of the nucleic acid. The invention also relates to the recombinant nucleic acid constructs, purified protein preparations and pharmaceutical compositions produced as well as methods of treatment utilizing the purified protein preparation.

Description: "IMPROVEMENTS IN PRODUCTION OF PROTEINS IN HOST CELLS" FIELD OF THE INVENTION The present invention relates generally to improved production of proteins in host cells. In particular it relates to improved production of proteϋns which are required for therapeutic or reagent applications and which are difficult to obtain in sufficient quantities. The invention also relates to a method of producing recombinant nucleic acid molecules which encode said proteins, to the recombinant nucleic acid molecules and recombinant constructs comprising the same and to the proteins produced thereby. Of particular interest are nucleic acid molecules encoding hormones, cytokines, growth factors, receptors and their ligands and cell surface proteins including complement regulating proteins. BACKGROUND OF THE INVENTION Although many genes and cDNAs encoding useful proteins have been isolated, a major problem facing scientists is the production of sufficient amounts of recombinant proteins for further study and for diagnostic or therapeutic applications. This is particularly so where commercial production of the protein is desired. In particular the production of hormones, cytokines, growth factors, receptors and their ligands and other proteins by recombinant means has become a major endeavour. By way of example the cell surface molecule, CD46 (also known as membrane cofactor or MCP) has not been expressed in eukaryotic hosts as well as other cDNA constructs using a variety of expression vectors. Similar concerns have arisen about CD55 (DAF) and CD35 (CR1) and factor H which like CD46, are members of the family of proteins called Regulators of Complement Activation (RCA). Regulators of Complement Activation control the amplification of the complement cascade. Each of the members of this family share structural characteristics, principally the -60-65 amino acid Short Consensus Repeat (SCR) modules, which are responsible for complement binding and regulatory functions. Genes encoding the family members are linked and map to chromosome lq3.2. The biology of these molecules is of interest in inflammation and homeostasis. However, there is currently a further application for them in the potential use of porcine organs or other organs for grafting to humans. Such xenogenic organs undergo antibod and complement mediated hyperacute rejection. A limitation to studies of CD46 and other RCAs has been that on transfection wit constructs encoding the recombinant proteins in either transient or stable systems very fe cells have been transfected and those that are express low amounts of protein. Indee in the inventors' laboratory and others, sophisticated cell sorting, cloning and selectio procedures have been necessary to isolate appropriate cells. This, in particular, ha created problems with the analysis of recombinant CD46, its physiological role and valu as a therapeutic agent. In work leading up to the present invention the inventors have surprisingly foun that alterations in a nucleic acid encoding CD46 led to high levels of CD46 productio in a transfected eukaryotic host. Protein production levels of up to 8 times that obtaine from the wildtype gene for CD46 have been observed. These alterations comprise reducing the amount or proportion of adenine (A) and/or thymine (T) in an A and/or rich region in the nucleic acid. The inventors are the first to discover that changes in the AT rich regions of exo result in increased protein production. SUMMARY OF THE INVENTION The present invention provides a method of increasing or improving protei production in a host cell where a nucleic acid encoding the protein has an A and/or T ric region present in an exon, said method comprising altering the nucleic acid by reducin or lowering the amount of A and/or T in said region and transfecting a host cell with sai nucleic acid and, under appropriate conditions, obtaining expression of said nucleic aci In another aspect the present invention provides a method for enhancin production of RCA proteins in a host cell where a nucleic acid encoding an RCA has a A and/or T rich region present in one or more of its exons said method comprisin altering the nucleic acid by lowering the amount of A and/or T in said A and/or T ric region, transfecting a host cell with said nucleic acid and, under appropriate condition obtaining expression of said nucleic acid. In another aspect the present invention relates to a method of increasing production of an RCA protein in a host cell comprising altering a nucleic acid encoding the RCA by deleting a SCR module which contains an AT rich region, or a part thereof, transfecting a host cell with said altered nucleic acid and under appropriate conditions obtaining expression of said nucleic acid. The present invention also relates to a recombinant nucleic acid construct which is capable of increased production of a protein in a host cell wherein the amount of A and/or T in one or more A and/or T rich regions present in one or more of the exons in a nucleic acid encoding the protein has been reduced. The present invention also relates to the proteins produced by the methods of the invention, to proteins encoded by the constructs of the invention, pharmaceutical compositions, host cells transfected with the constructs and transgenic animals expressing the proteins. The present invention also relates to a method of producing an altered gene encoding a protein wherein said altered gene is capable of increased production of the protein said method comprising altering a gene with one or more A and/or T rich regions present in one or more exons by reducing or lowering the amount of A and/or T in said regions. Brief Description of the Figures Fig 1. Sequence ofCD46 constructs in the mutated SCR2 and SCR3 regions. Numbering of the sequence is based on the cDNA clone pm5.1 (Purcell et al., 1991) and extends from the end of SCR1 at nucleotide 303 (nt303) to the beginning of SCR3 (nt564). SCR junctions are shown. The sequence for the construct wtSCR (equivalent to pm5.1) is shown in full with the corresponding single letter code amino acid sequence given above it. Nucleotides which have been substituted in any of the constructs are underlined. For the subSCR2, subSCR3 and subSCR2+3 constructs the sequence matching wtSCR is shown with a dot (.) and the substituted nucleotide is indicated. The deletion mutant construct is as for the other constructs except that the SCR2 deletion is indicated by blanks. Fig 2. Flow cytometry of COS cells after transient transfection with wildtype and mutan constructs. Flow cytometry was performed as described in Materials and Methods. Al cells were stained with CD46 mAb E4.3. Panel A shows mock transfected COS cell Panel B shows profiles for wtSCR transfected cells (---) overlayed with subSCR transfected cells ( ); panel C shows wtSCR( — ) overlayed with subSCR3 ( ) panel D shows wtSCR (— ) overlayed with subSCR2+3 ( ); panel E shows wtSC ( — ) overlayed with delSCR2/subSCR3( ). The mutated constructs generated a profil shifted to the right in each case. Fig 3. Western blot analysis of COS cell lysates transfected with CD46 constructs (se Materials and Methods). Lanes contain 40μl of a dilution of cell lysate at 5 x 10 6 cell per ml. From left to right lanes contain transfectant WOP-5.10L (CD46 BC2) at 1/ dilution; COS cell lysate transfected with no DNA at 1/10 dilution and 1/50 dilutio COS cell lysate transfected with wtSCR2 at 1/10 and 1/50 dilution; COS cell lysat transfected with subSCR2 at 1/10 and 1/50 dilution; COS cell lysate transfected wit subSCR3 at 1/10 and 1/50 dilution; and COS cell lysate transfected with subSCR2+3 1/10 and 1/50 dilution. Molecular weight markers are indicated. Fig 4. Semi -quantitative radioimmunoassay (see Materials and Methods) of COS ce lysates. An equivalent number of transfected cells was used for each sample. The mea number of counts bound (duplicates) with standard error is shown against dilution facto The titration curves are for lysates of mock (■), wtSCR (o) and subSCR2+3 (• transfected cells. Fig 5. Western blot analysis of COS cell serum-free supernatant 168 hours aft transfection with CD46 constructs (see Materials and Methods). Lanes contain 40 μl undiluted supernatant. From left to right lanes contain supernatant from cells transfecte with the cell surface construct subSCR2+3; the soluble construct sol-wtSCR; blank; th soluble construct sol-subSCR3; and no DNA (mock). Molecular weight markers ar indicated. Fig 6. Semi-quantitative radioimmunoassay (see Materials and Methods) of COS cell supernatants. An equivalent amount of tissue culture supernatant was used for each sample. The mean number of counts bound (duplicates) is shown against the dilution factor. The titration curves are for supernatants of mock (■), sol-wtSCR (o) and sol- subSCR3 (•) transfected cells. Fig 7. Northern blot analysis of CD46 mRNA in transfected COS cells. Total RNA prepared from COS cells 48 hours after transfection was separated by electrophoresis (10 μg/track). Northern blotting was as described in Materials and Methods. The position of the 28S and 18S ribosomal RNA bands are indicated. Lanes 1-5 contain RNA prepared from COS cells transfected with no DNA, wtSCR, subSCR2, subSCR3 and subSCR2+3, respectively. Fig 8. Southern blot analysis of CD46 mRNA in transfected COS cells. DNA prepared from COS cells 48 hours after transfection was separated by electrophoresis (5 μg/track). Southern blotting was as described in Materials and Methods. Lanes 1 -5 contain DNA prepared from COS cells transfected with no DNA, wtSCR, subSCR2, subSCR3 and subSCR2+3, respectively. Fig 9. Flow cytometry of CHO cells after stable transfection with wildtype and mutant constructs. Flow cytometry was performed as described in Materials and Methods. All cells were stained with CD46 mAb E4.3. Panel A shows pgk-neo transfected CHO cells. Panel B shows profiles for wtSCR transfected cells ( ) overlayed with subSCR2 transfected cells ( ); panel C shows wtSCR ( — ) overlayed with subSCR3 ( ); panel D shows wtSCR (— ) overlayed with subSCR2+3 ( ). Fig. 10. In vitro translation of synthetic CD46 transcripts. Lanes contain 35 S-methionine labelled in vitro translation products from capped mRNAs as labelled. The arrow indicates the non glycosylated protein of the expected size, and the molecular weight markers are shown. Fig. 11. Semi-quantitative radioimmunoassay (see Materials and Methods) of CHO-K cell lysates. An equivalent number of transfected cells was used for each sample. Th mean number of counts bound (duplicates) with standard error is shown against dilutio factor. The titration curves are for lysates of mock (■), soluble wtSCR (D) and solubl subSCR3 (•) transfected cells. Summary of Sequence listings Seq ID No. 1 The cDNA sequence of wtSCR showing amino acid translation Seq ID No.2 The cDNA sequence of subSCR2 showing amino acid translatio Seq ID No.3 The cDNA sequence of subSCR3 showing amino acid translatio Seq ID No.4 The cDNA sequence of subSCR2+3 showing amino acid translatio Seq ID No.5 The cDNA sequence of delSCR2subSCR3 showing amino aci translation Detailed Description of Preferred Embodiments In a first aspect the present invention provides a method of increasing improving protein production in a host cell where a nucleic acid encoding the protein h an A and/or T rich region present in an exon, said method comprising altering the nucle acid by reducing or lowering the amount of A and or T in said region, transfecting a ho cell with said nucleic acid and, under appropriate conditions, obtaining expression of sa nucleic acid. The phrase "increasing or improving protein production" refers to causing high production of the desired protein than would routinely be expected in an host cell a includes enhancing protein production. The method of the present invention particularly directed to providing greater protein production levels where production leve are less than optimal but is not limited to this situation. The term "host cell" means any cell capable of expressing the nucleic ac encoding the protein. Both prokaryotic and eukaryotic host cells are contemplated. The term "nucleic acid encoding a protein" refers to a nucleic acid comprisi DNA or RNA and includes genes containing introns and exons and cDNA molecule The term also includes nucleic acids comprising or containing synthetic purine a pyrimidine bases. The phrase "A and or T rich region" denotes a stretch of nucleotides which contains a higher than average amount of A and/or T, and may alternatively be referred to as an "AT rich region". This means a stretch of nucleotides with a greater than average AT content for the particular species from which the nucleic acid is derived. For instance an AT rich region in a nucleic acid encoding a human protein would be a region that contains more than 60% A and/or T in a particular span of nucleotide sequence. It should be understood that the term AT rich region includes an AU rich region (where RNA is the nucleic acid) and that "A and/or T" also means "A and or U" in an RNA context. The term "exon" means that part of a nucleic acid actually encoding the protein. The phrase "altering the nucleic acid by reducing or lowering the amount of A and/or T, in said region" means that A and/or T nucleotides in the AT rich region are replaced by substitution of other bases (such as G or C, or synthetic nucleotides) or that these nucleotides are deleted and not replaced by another base. Usually such a deletion will be an "in frame" deletion thus not producing a frame-shift. The reduction or lowering the amount of A and or T includes reference to lowering the proportion of A and/or T with respect to G and or C nucleotides. The term "mutation" is also used to refer to such alterations throughout the specification. Where the nucleotides are replaced by other bases the resultant alteration may be silent so that the codon encodes the same amino acid. Silent mutations are well known to those skilled in the art and most commonly involve changing the third nucleotide of the codon. Alternatively, the replacement may be conservative, i.e. results in a codon specific for an amino acid with similar properties to the original amino acid specified. Suitable conservative amino acid substitutions are given in Table A below. Those skilled in the art will know which bases to substitute to confer a conservative amino acid substitution. Typical substitutions are those made in accordance with Table A. TABLE A Suitable residues for amino acid substitutions Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gin; His Asp Glu Cys Ser Gin Asn Glu Ala Gly Pro His Asn; Gin He Leu; Val Leu He; Val Lys Arg; Gin; Glu Met Leu; He Phe Met; Leu; Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp; Phe Val He; Leu Alternatively an entirely different codon may be created by insertion of nucleotide other than A or T depending on the protein product desired. It will b understood that this will usually be an in frame insertion. The term "transfecting" means causing the nucleic acid to be taken up by the cell The nucleic acid will usually be present as a component of an expression vector or th like. The resultant transfection may be transient, where the gene is maintained on a episome, or stable. Stable transfection is achieved where the gene is integrated into th cell genome and becomes stably heritable. Nucleic acids can also be introduced into hos cells via viral vectors by infection of host cells with, for example, recombinant vaccini or adenoviruses. The method of the invention contemplates increasing production of all proteins encoded by nucleic acids with AT rich regions in their exons where it is desired to produce the proteins in an eukaryotic system. The nucleic acids encoding candidate proteins may be screened for AT rich regions in their exons by standard techniques such as searching the GenBank data base. These nucleic acids include those encoding cell surface proteins, peptide hormones, cytokines, growth factors, receptors and their ligands, novel recombinant proteins for therapeutic uses or reagents where it is desired to increase production of the protein. Complement regulating proteins, particularly those containing short consensus repeat domains, such as CD46, are of particular interest. The prokaryotic cell used in the method may by any prokaryotic cell suitable for expressing the required gene. This includes Escherichia coli (for example E. coli MC1061 , E. coli DH5 α , E. coli NM522, EK12 and E. coli W31 10), bacilli such as Bacillus subtilis or other enterobacteriaciae such as, for example, Salmonella typhimurium or Serratia marcesans and various Pseudomonas species. Preferably non-pathogenic, attenuated strains of these organisms are used. The eukaryotic cell used in the method may be any eukaryotic cell suitable for expression of the required gene. Suitable cells which will be known by those skilled in the art, include animal cells such as COS-7, CHO-K1 , WOP-3027, C127, VERO, HeLa, W138, BHK, 293, MDCK and L929. Others such as Saccharomyces, Kluyveromyces, Pichia pastoris, Schwanniomyces and Hansenula may also be suitable. Suitable vectors used to transfect the host cell with the nucleic acid in the method will be well known to those skilled in the art. Suitable prokaryotic vectors include pGEX, pKC30, pKK173-3, pET-3 and others. These vectors will preferably contain replicon and control sequences that are compatible with the chosen host cell described above. For example, in mammalian cells the control functions on eukaryotic expression vectors are usually provided by viral sources such as Adenovirus 2, polyoma, HIV-1, human cytomegalovirus and SV40. The phrase "under appropriate conditions" means conditions suitable to obtain expression of the nucleic acid and production of the protein. Culture conditions such as nutrients, temperature and so on will be well known to those skilled in the art. There appears to be a number of possible mechanistic explanations for the increased level of protein production provided by lowering the A and or T content of t AT rich regions present in an exon. Examples include improved stability of transcrip increased delivery of mRNA to the cytoplasm, increased efficiency of translation ribosomes, increased translation due to mRNA superstructure or in fact a combination two or more of these factors. Without wishing to be bound by theory it appears like that the increased protein production can be explained by an increased rate of prote translation. Data indicating that the increased protein production is limited to intact ce and is not evidenced in cell-free translation systems tends to indicate the effect is due some interaction between mRNA, transcripts, ribosomes, polysomes, RNA-bindi proteins and or other factors such as sequence-dependent 3-dimensional mRNA structu rather substrate availability or simple structural effects or simple protein translati component interaction. While there is still some speculation about the exact mechamism responsible the improved protein production associated with the present invention, it is nonthel noted that protein production increases of up to or exceeding 20-fold in terms of ce surface molecule expression can be obtained. The increased protein production appe to be most pronounced, especially in the case of CD46 translation, when the reduction A and/or T content is effected within a region up to about 540 bases from the initiati codon. In a preferred embodiment the host cell used in the method is a eukaryotic ce This is because it is often desirable to obtain post-translational modifications of t recombinant protein, such as glycosylation which cannot always be provided prokaryotic hosts and some insect cells. In another preferred embodiment the nucleic acid encodes an RCA which has A and/or T rich region in one or more of its exons. The RCA may be CD46, CD CD35 or factor H amongst others. In a particularly preferred embodiment the present invention relates to a meth of increasing or improving CD46 production in a eukaryotic cell where the gene encodi CD46 is altered by reducing or lowering the amount of A and/or T in an A and T ri region in one or more exons of said gene and transfecting a eukaryotic cell with s altered gene and, under appropriate conditions, obtaining expression of said gene. The term "CD46" used herein refers to all native isoforms and recombinant splice variants, including native forms not commonly expressed by human cells. Any CD46 gene natural or recombinant may be used as a starting point for synthesis of the altered CD46 gene. This includes the native CD46 genes and the CD46 constructs disclosed in PCT/AU91/00199 (the specification of which is herein incorporated by reference). cDNA CD46 constructs which by definition comprise exons are preferred. In the Examples herein clone pm5.1 of PCT/AU91/00199 is used as a starting point. In a particularly preferred aspect of the invention the alterations are made to AT rich regions encoding the short consensus repeat (SCR) domains or to putative polyadenylation signals. This is particularly so when putative polyadenylation signals occur inappropriately within protein-coding exons. More particularly preferred are alterations to the boundary or junction, surrounding the 3rd and 4th exons in CD46 cDNA constructs. The 3rd and 4th exons encode one of the SCRs and contains a stretch of 49 nucleotides 78% which are A or T which may be altered. In addition, alterations to a smaller A rich region within the adjacent exon 5 may also be carried out separately or in conjunction with the above alterations. Although exons 3, 4 and 5 have been the target for the alterations so far described other regions of the CD46 gene may be contemplated such as exons 6 and 14. The alteration may be made by replacing the A or T nucleotides with other bases or deleting the A or T nucleotides and not replacing them with other bases as described above. The substitutions will depend on the structure of the protein required and may be silent or conservative. Still more preferably the AT content of the region between nucleotides 406 to 454 of Figure 1 is reduced from 78% to approximately 60%, more preferably approximately 55%. Alternatively, still more preferably the A rich region in SCR3 is reduced, which interrupts a putative poly A signal on the wildtype CD46 gene, and the nucleotides substituted extend 5' to the end of the region encoding SCR2. Alternatively more preferably the SCR2 is deleted and optionally there are substitutions in the SCR3. In addition to the above alteration mutations can also be made which render the CD46 protein soluble. Preferably a stop codon is created for example at position 10 of pm5.1 (Purcell et al (1991)) by changing an A to a G. In a still more preferred form the invention relates to a method of using t constructs of subSCR2, subSCR3, subSCR2/3 and delSCR2/subSCR3 as illustrated Figure 1. By way of explanation a construct containing substitutions in exons 3 and are denoted subSCR2, substitutions in exon 5 is denoted subSCR3 and substitutions exons 3, 4 and 5 are denoted subSCR2+3. The construct which comprises deletion SCR2 and contains a substitution in SCR3 is designated delSCR2/subSCR3. Where substitution of A or T nucleotides is desired splice overlap extension (SO PCR) may be used. Other methods such as PCR based mutagenesis, and ligation of appropriately mutated synthetic nucleotide will be known to persons skilled in the a Deletion of A or T nucleotides or stretches of nucleotides may be carried out by standa site directed mutagenic techniques. Preferably the initial constructs containing the altered CD46 cDNA are made bacterial vectors. Once it has been confirmed that the desired construct has be produced then the altered CD46 gene may be ligated into a eukaryotic vector such pcDNAl, pCDM8, PGK-neo, pEE6.hCMV.GS, pHIV, pHMG or pMJ601 and others. The desired construct containing the altered gene is then used to transfect appropriate host cell. Preferably this is a eukaryotic host cell. Standard transfecti techniques may be employed preferably using Lipofectamine (Gibco-BRL, Gaithersbu USA) or a similar reagent. COS-7 or CHO-K1 cells are preferably transfected althou other eukaryotic cells may be utilised such as WPO-3027, L929 and so on. In a related aspect the present invention provides a method for enhanci production of RCA proteins in a host cell where a nucleic acid encoding an RCA has and/or T rich regions present in one or more of its SCR modules, said method comprisi altering the nucleic acid by lowering the amount of A and or T in said A and/or T ri regions, transfecting a host cell with said nucleic acid and, under appropriate conditio obtaining expression of said nucleic acid. The terms "A and or T rich region" and "lowering the amount of A and or have the same meaning as given above. Preferably a eukaryotic host cell is used in the method such as those describ above. More preferably the AT rich regions in SCR2 and SCR3 are subject to alteration. The above method is based on the observation that alterations in nucleotides encoding the SCR2 and SCR3 modules in CD46 produce an additive effect which greatly increases the amount of protein produced. Preferably the nucleic acid encodes CD46. Preferably the alteration is obtained through silent nucleotide substitutions. More preferably the nucleic acid is the construct subSCR2+3 described herein. In a second aspect the present invention relates to a method of increasing production of an RCA protein in a host cell comprising altering a nucleic acid encoding the RCA by deleting one or more SCR modules with contains an AT rich region, or a part thereof, transfecting a host cell with said altered nucleic acid and under appropriate conditions obtaining expression of said nucleic acid. Preferably a eukaryotic host cell, such as those described above is employed in the method. Optionally, in the above method other parts of the nucleic acid, including AT rich regions outside of the SCR module(s) may also be changed such as by reducing the amount of A and/or T in the AT rich region. Preferably the altered nucleic acid encodes a CD46 isoform. More preferably the nucleic acid encoding CD46 is delSCR2/subSCR3 described herein. In a third aspect the present invention also relates to a recombinant nucleic acid construct which is capable of increased production of a protein in a host cell wherein the amount of A and/or T in one or more A and/or T rich regions present in one or more of the exons has been reduced. The term "recombinant nucleic acid construct" refers to a molecule made up of nucleic acids which have been combined from different sources and is capable of transfecting a host cell. The term "increased production" refers to expression levels higher than that demonstrated in previous constructs including those containing native genes encoding the protein of interest. The terms "A and or T rich region", "exon", "host cell" and reduction of the amount of the A and/or T in the A and/or T rich region have the same meanings as given earlier. Such constructs may be produced by the methods given earlier. Preferably the host cell is a eukaryotic host cell. Preferably the constructs comprise nucleic acids which encode proteins, the gene of which in their native state contain A and or T rich regions in their exons. The nuclei acids may encode proteins such as cell surface proteins, peptide hormones, growth factor receptors and their ligand, novel recombinant proteins for therapeutic uses or reagent Complement regulating proteins, particularly those containing short consensus repe domains are included. In a particularly preferred aspect of the invention the constructs encode an altere CD46 cDNA sequence. While any CD46 cDNA may be used as a starting point thos disclosed in PCT/AU91/00199 (which is incorporated herein by reference), particularl clone pm5.1 are preferred. In a more preferred aspect the construct comprises alterations in one or more the following AT rich regions of Fig 1 of the CD46 construct, or its equivalent nucleotides 406 to 454, 504 to 516 and 530 to 561. In a preferred aspect of the invention the CD46 constructs of the invention hav been altered so that the proportion or amount of A and/or T in the AT rich regions of th SCR domains has been reduced and optionally the putative poly A signal have bee removed. In a more preferred aspect of the present invention the construct compris alterations which have reduced the amount of A and or T in the AT rich region of th boundary or junction surrounding the 3rd and 4th exons. Still more preferred is a construction comprising a reduction of A and/or T in th 49 nucleotide stretch 78% of which comprises A and/or T in the 3rd and 4th exons or reduction in the A rich region within the adjacent exon 5. In a most preferred aspect the invention relates to the constructs subSCR subSCR3, subSCR2+3 and delSCR2/subSCR3. The above constructs or their derivatives which result in production of CD46 the cell surface may be used to produce transgenic animals such as transgenic pigs who organs produce cell surface CD46. Such organs may be used in transplantation therap The term "derivative" above means recombinant constructs containing the altered CD4 gene or gene segments derived from the above constructs. The present invention also relates to a purified preparation of a protein produced by the first and second aspects of the invention and to a purified preparation of a protein encoded by the constructs of the third aspect of the invention. The term "purified preparation" refers to preparation of proteins separated from, in at least some degree, the proteins and other constituents of the host cell. Preferably the protein is at least 50% pure, preferably 60% pure, more preferably 70% pure, still more preferably 80% pure and still more preferably 90% pure, or more, when compared to other proteins or constituents as determined by weight, activity, amino acid similarly antibody reactivity or other convenient means. Preferably the protein is CD46BC1. Most preferably the invention relates to a soluble CD46 (sCD46(BC)) protein encoded by sol-subSCR3 (see Table 1) as described or an equivalent. The invention also relates to host cells expressing the desired protein made in accordance with the first and second aspects of the invention or transformed with the constructs of the third aspect of the invention. In a particularly preferred aspect the invention relates to stably transfected host cells or transgenic animals expressing the desired protein. The invention also relates to a method of producing an altered gene encoding a protein wherein said altered gene is capable of causing increased production of the protein said method comprising altering a gene with one or more A and/or T rich regions present in one or more exons by reducing or lowering the amount to A or T in said regions. The terms, phrases and methods for producing the altered gene used above have been explained earlier. Preferably the altered gene is capable of causing increased production of a protein in a eukaryotic host cell. Preferably the altered gene comprises a CD46 encoding segment. Preferably the primers described in Table 1 are used in splice overlap extension PCR to produce the altered CD46 gene. In another aspect the present invention comprises a pharmaceutical composition comprising as an active ingredient a purified protein preparation described above together with a pharmaceutically appropriate carrier or diluent. The pharmaceutical composition may be used in the treatment of diseases for which the active ingredient is indicated. In the case where the active ingredient is CD46 then the composition may be used to prevent complement mediated, or inflammation mediated tissue damage, to enhance immunity to tumours and viruses, to control the process of fertilization, to prevent recurrent spontaneous abortion of the foetus during pregnancy and to facilitate engrafting of transplanted tissue as previously described in PCT/AU91/00199 which is incorporated herein by reference. The formation of pharmaceutical compositions is generally known in the art and reference can conveniently be made to Remington's Pharmaceutical Sciences, 17th ed, Mack Publishing Co, Pennsylvania, USA. In a preferred aspect the present invention comprises a pharmaceutical composition comprising CD46 made according to the above methods or derivable from the above constructs together with a pharmaceutically appropriate carrier or diluent. In a particularly preferred aspect the present invention comprises a pharmaceutical composition comprising the soluble CD46 protein as herein described. The invention will be further described with reference to the following non- limiting examples. EXAMPLE 1 Materials and Methods The CD46 isoform nomenclature The CD46 gene produces 4 commonly expressed mRNAs (up to 14 in total) by alternative RNA splicing (Russell et al., 1992). To simplify representation of CD46 protein isoforms only the variably spliced regions, the STP-A,B,C segments (encoded by exons 7, 8 and 9) and cytoplasmic tails (tail 1 is encoded by exon 13, whereas tail 2 is encoded by exon 14 after the splicing out of exon 13) are denoted unless mutated for the purposes of the present application. The term "mutated" used here means the same as the alterations discussed earlier. The wildtype protein isoform produced in this application includes STPs B and C (exons 8, 9) and cytoplasmic tail 1 (exon 13) and is denoted by CD46(BCl)(the equivalent protein is encoded by pm5.1 cDNA in Purcell et al, 1991 and PCT/AU91/00199). The protein isoform containing STPs B and C and cytoplasmic tail 2 is denoted by CD46(BC2). The soluble protein produced here is referred to as sCD46(BC), because the stop codon is at the predicted transmembrane boundary. Nucleotide substituted constructs and products are designated by the protein domain encoded by the targeted exons. Thus the construct containing substitutions in exons 3 and 4 is subSCR2; substitution to exon 5 is subSCR3; and substitutions to exons 3, 4 and 5 is subSCR2+3. The construct which encodes an SCR2 deletion and contains SCR3 substitutions is designated delSCR2/subSCR3. Mutagenesis of CD46 cDNA Silent nucleotide substitution was achieved using Splice Overlap Extension PCR (SOE-PCR) (Horton et al, 1988). Firstly, two PCR reactions amplified two overlapping DNA fragments which contained the required mutations in complementary sequences at one end and EcoRl sites at the other end. Secondly, the two fragments were spliced together in a SOE-PCR reaction using the primers containing the EcoRl sites. The PCR primers and the nucleotide positions to which they annealed are shown in Table 1 A. The overlapping DNA fragments containing mutations were produced in two PCR reactions using the templates and oligonucleotide combinations shown in Table IB. The products of the first two PCR reactions for each mutant, the 5' and 3' PCR fragments, were isolated after electrophoresis in low-melt agarose (Nusieve), diluted and used directly as template for the SOE-PCR reactions. All the SOE-PCR reactions, including the unmutated wildtype CD46, used On232 and On241 as oligonucleotides. The PCR and SOE reactions were performed in a DNA Thermal Cycler (Perkin Elmer Cetus) using Amplitaq enzyme and buffer (Perkin Elmer Cetus). The cycle conditions for the first two PCR were 3 cycles of 2 min at 94° C, 1 min at 50° C and 1 min at 72° C, followed by 22 cycles of 30 sec at 94° C, 1 min at 60° C and 1 min at 72° C. The SOE-PCR cycle conditions were 3 cycles of 2 min at 94° C, 1 min at 44° C and 2 min at 72° C, followed by 22 cycles of 30 sec at 94° C, 1 min at 60° C and 2 min at 72° C. While not wishing to be bound by theory the above mutations appear to restore the usual AT/GC balance (proportion of AT:GC) found in mammalian nucleic acids and this restoration of balance appears to result in increased protein production. Mutant DNA constructs and expression vectors PCR products were end-filled with DNA polymerase (Klenow fragment) (Boehringer Mannheim) and phosphorylated with T4 polynucleotide kinase (New England Biolabs). The DNA was purified after agarose gel electrophoresis using NA45 paper (DEAE)(Schleicher and Schuell) followed by MagicPrep DNA clean-up system (Promega Corp.). The DNA products were ligated (DNA ligase, New England Biolabs) into the Sma I site of pBluescript II SK (Stratagene) and transformed into XL1 Blue E. coli (Stratagene). Plasmid DNA was prepared of clones containing mutations using Maxiprep (Promega Corp.) and the entire sequence was confirmed by dideoxy sequencing using a Sequenase™ kit (United States Biochemical Corp.). All products contained the nucleotide mutations without PCR error. The DNA inserts were released from the pBluescript vector by digestion with Eco Rl, end-filled with DNA polymerase (Klenow fragment) (Boehringer Mannheim), ligated into the Eco RV site of pcDNA I (Invitrogen Corp.) and transformed into MC1061/p3 E. coli. The cloning sites were confirmed by dideoxy sequencing. Plasmid DNA for transfection was prepared using Wizard™ Maxiprep DNA purification system (Promega Corp). Transfection COS-7 green monkey fibroblasts and CHO-Kl Chinese hamster ovary fibroblasts were cultured in DMEM medium supplemented with 20 μg/ml glutamine, 100 U/ml penicillin, 100 μg ml streptomycin, and 10% v/v foetal bovine serum (CHO-Kl medium also contained 20 μg/ml proline, 14 μg/ml hypoxanthine and 3.9 μg ml thymidine), in a humidified 10% CO 2 atmosphere. Plasmid DNA (pcDNAl-CD46 constructs) was introduced into cultured cell lines with Lipofectamine (Gibco-BRL) in serum-free and antibiotic-free DMEM medium, according to the manufacturer's instructions. One six- well plate of COS-7 cells was transfected with each construct. The cells transfected with cell-surface CD46(BC1) were harvested 48 hours after transfection and were split into aliquots to be analysed by Southern, Northern and Western blotting, radioimmunoassay (RIA) of cell lysates, fluorescent microscopy and flow cytometry. For the expression of soluble CD46 constructs, ϋhe COS-7 cells were cultured in serum-free medium which was collected 120 or 148 hours after transfection. For generation of transfected CHO-Kl cells with stable construct integration, PGK-neo plasmid (a gift from Dr Richard Harvey, WEHI, Melbourne, Australia) was cotransfected, with a 10-fold excess molar concentration of the pcDNAl-CD46 construct plasmid DNA. Transfected CHO cells were selected for stable expressors with 1.2 mg/ml G418 and assayed for cell surface expression of CD46 after two or more weeks. Analysis of cell surface CD46(BC1) production by immunofluorescence CD46 protein processed on the plasma membrane, or as intracellular protein in permeabilised cells, was assayed by two-stage immunofluoresence labelling. The primary anti-CD46 Ab (E4.3 IgG2a, Sparrow & McKenzie 1983; or M177 IgGl , Seya et al, 1990) or isotype control mAb (MEM-43 IgG2a anti-CD59, Stefanova et al, 1989) was incubated with cells for more than 30 min on ice, cells were washed and FITC sheep(Fab)-anti-mouse Ig (Silenus, Melbourne, Australia) was added for a further 30 min on ice. Fluorescence was assessed by flow cytometry (FACScan II, Becton Dickinson) of cell suspensions or by microscopy of near-confluent cell monolayers. Analyses of CD46(BC1) in whole cell lysates Whole cell lysates were prepared as described at a concentration of 5 x 10 6 cells/ml. An equivalent number of cells was used for all samples and Western blotting was performed as described (Laemmli, 1970). The proteins present in the lysate were separated by non-reducing SDS-PAGE, blotted and probed with the mAb E4.3. The capture/tracer RIA used mAb E4.3 to capture the CD46 protein and l 5 I-labelled Ml 77 (a gift from Seya) as the tracer and was performed as described, but with approximately 10 000 cpm input counts of the tracer (Johnstone et al., 1993). Analyses of DNA and RNA RNA was prepared using a modification of the procedure of Chirgwin et al. (1979). Northern blotting was performed as described (Milland et al., 1990) except that the membrane was Hybond-N (Amersham) and the transfer was by gravity in a downwards direction. Cellular DNA was prepared and Southern blotting was performed as described (Southern) using Hybond-N + (Amersham) as the membrane. For the Northerns and Southerns the probe used for hybridisation was pm5.1 cDNA (Purcell et al, 1991), labelled using the Megaprime DNA Labelling System (Amersham). Plasmid constructs The sequences of the SCR mutation are shown in Figure 1. All the final constructs were in the pcDNAl vector and had the same cloning sites derived from th oligonucleotides used for the PCR. The construct containing unmutated (wtSCR) sequence is derived from the original pm5.1 cDNA clone (Purcell et al., 1991). This an each of the silent substitution constructs discussed below encodes wildtype CD46(BC1 protein. The subSCR2 construct contains silent nucleotide substitutions in the region i SCR2 around the exon 3/4 splice site and encodes wildtype CD46(BC1) protein. Th substitutions reduce the A/T content of the region between the nucleotides 406 and 45 from 78% to 55%. The subSCR3 construct contains silent nucleotide substitutions to a A-rich region in SCR3 (including one substitution at the end of SCR2) and also interrupt a putative polyadenylation signal and encodes wildtype CD46(BC1) protein. Th subSCR2+3 construct contains a combination of the SCR2 and SCR3 changes an encodes wildtype CD46(BC1) protein. The final cell surface construct delSCR2/subSCR3, has SCR2 deleted and substitutions to SCR3. This construct encode a mutant protein without SCR2, called CD46(delSCR2/BCl). Two DNA constructs wer mutated to encode a soluble protein called sCD46(BC). The first construct, sol-wtSC was produced by the substitution of an A for a G at nucleotide 1022 to produce a sto codon before the transmembrane domain. The sol-subSCR3 construct contains the sto codon mutation and the silent nucleotide substitutions in SCR3 described above. Silent nucleotide substitution increases the production of cell surface CD46(BC1) Initially the inventors showed that mutation increased protein production CD4 by photomicrography. In these experiments cells were transfected in wells and staine with E4.3. Results are not shown. The order of increasing protein production wa wtSCR, subSCR2, subSCR3, subSCR2+3 and delSCR2/subSCR3. The improvement i CD46 production was also observed after transfection of WOP-3027 cells (data no shown). Flow cytometry showed that more COS-7 cells were producing CD46 on thei surface and that the cells were also producing at a significantly higher level afte transfection with the mutated constructs compared to the wtSCR construct (Figure 2) The improvement in production was in the same order as for the photomicrography. A would be expected, a proportion of the cell population has a similar fluorescence to the mock transfected cells and represent untransfected or transfected cells without cell surface CD46, however, in panels C, D and E, it appears that all cells exposed to the mutated constructs were transfected and expressed CD46: the entire profile in each case is shifted to the right in comparison to the profile of wildtype transfected cells. Silent nucleotide substitution increases the production of CD46(BC1) in cell lysates Cell lysates were prepared from transfected cells. These lysates include all cells that were transfected including the large proportion of cells that do not produce significant amounts of cell surface CD46. In all cases, the protein produced after transfection of CD46(BC1) was the expected size (66 kDa) by Western blotting (Figure 3). There is more CD46 in the lysates from cells transfected with mutated CD46 DNA compared with unmutated CD46 DNA. The order of improvement in production was the same as for cell surface expression and cells transfected with the subSCR2+3 construct gave the best result compared to the wtSCR construct. To enable a better estimate of the difference in the level of CD46 proteins, RIA was performed (Figure 4). The population of cells transfected with subSCR2 or subSCR3 had approximately twice as much CD46 in their lysates compared to the wtSCR transfected cells. The cells transfected with subSCR2+3 had approximately eight times as much CD46 in their lysates compared to the wtSCR transfected cells. These results suggest that the nucleotide sequences in SCR2 and SCR3 may be interacting in some way, since the silent substitutions to SCR2 and SCR3 appear to improve the level of protein expression in an additive way. There may also be other nucleotide sequences in SCR2 affecting the level of protein expression, since the total deletion of SCR2 increases the level of expression more than the silent nucleotide substitutions of SCR2+3. Silent nucleotide substitution increases the production of soluble CD46(BC) The silent nucleotide substitutions in SCR3 also enabled significantly greater quantities of sCD46(BC) to be expressed in a transient COS system. The sol-subSCR3 construct produced protein detectable by Western blotting in the serum-free supernatant of cells 148 hours after transfection of COS-7 cells (Figure 5). Supernatant from similarly transfected cells 120 hours post-transfection was analysed by RIA. The level of soluble material secreted by cells transfected with sol-subSCR3 was approximately nine times that of cells transfected with sol-wtSCR (Figure 6). COS cells transfected with the subSCR2+3 (shown in Figure 5) or delSCR2/subSCR3 (data not shown) also shed or secreted significant amounts of CD46 protein into the tissue culture supernatant which was in addition to CD46 expressed on the cell surface. None of the other cell surface transfectants produced detectable quantities of CD46 in the supernatant. The increase in production of CD46(BC1) caused by silent nucleotide substitutions does not appear to be due to increases in expression of mRNA or of transfected DNA Total RNA was prepared from populations of cells transfected with the variou constructs and level of mRNA expression was determined by Northern blot (Figure 7). The level of mRNA in total RNA was similar for constructs containing the silen mutations compared with the level for the unmutated wtSCR construct (Figure 7). Thi level of expression represents that of the total cell population and does not indicate the level of expression per cell. The amount of plasmid present in the population of cells was determined by Southern blotting (Figure 8) and was not significantly different for any of the constructs. Silent nucleotide substitutions increase the production of CD46(BC1) in a stable transfection system After transfection and G418 drug selection, CHO-Kl transfectants were analysed by flow cytometry. Populations of selected cells transfected with constructs containing silent mutations contained more cells expressing CD46 and they expressed CD46 to much a higher level (Figure 9), with the greatest increase observed for the subSCR2+3 construct (panel D). EXAMPLE 2 Preparation of mutagenised CD55 constructs. A particular example for application of the invention can be provided by th nucleic acid encoding CD55 (DAF: Decay Accelerating Factor), a structurally relate RCA molecule. The CD55 gene has AT-nucleotide rich regions within exons encoding the SCR2, SCR3 and SCR4 modules of CD55. Silent nucleotide substitutions are directed individually toward the sequences included within residues 388 to 412 (encoding SCR2); 590 to 602, 633 to 645 and 658 to 674 (encoding SCR3); 718 to 728 and 844 to 854 (encoding SCR4). The particular PCR primers for mutagenesis are designed to reduce the A and/or T content of the codons for these regions without altering the predicted amino acid sequence, which would be clear to one skilled in the art, but have sufficient lengths of sequence complementary to the cDNA template to enable priming of the initial PCR. Numbering of the CD55 gene is according to Fig. 3 of Lublin and Atkinson (Curr Top Micro Immunol 153, 123, 1989). These primers are designed in complementary pairs (forward and reverse primers in 5' and 3' directions) to allow annealing of the mutated PCR products in the Splice-Overlap Extension PCR as described specifically above. Additional forward and reverse PCR primers are designed, containing restriction enzyme cleavage sites, which anneal to the wildtype cDNA template at positions flanking the 5'-UTR and 3' of putative polyadenylation signals in the 3'-UTR, as is obvious to one skilled in the art. The six AT-rich sequences identified and listed above may variously accord with the requirements for augmented production of the protein in transfected cells. Each mutated construct is created individually, and combinations including multiple mutated spans of nucleotide sequence can be additionally prepared. The PCR products are purified and cloned into the SK vector for complete sequencing to confirm integrity of the required mutated sequence, before cloning into the appropriate expression vector (e.g., pcDNAl) and transfection into eukaryotic cells. Production of the CD55 protein is assessed by flow cytometry using the 1H4 anti-CD55 monoclonal antibody, and the relative expression of CD55 in transfected cells is correlated with the mutagenised construct. Thus the hierarchy of mutations affecting protein translation can be constructed. Cells transfected with the optimal constructs are further tested for protection against complement-mediated lysis mediated by the expressed CD55, as decay- accelerating activity. This assay proves that the protein is appropriately expressed and is functioning normally. EXAMPLE 3 Summary of CD46-transfection data Nucleotide constructs, either of wild-type or mutated (substitution) forms, were cloned into the expression vectors: pcDNAl (as already described); and APEX-3. These expression constructs were transfected into cultured mammalian cell lines. Transfections were repeated to ensure that any variations in expression recorded were consistent and not erratic artefacts. The pcDNAl vector constructs in COS-7 cells (transient expression) were variously expressed, depending on the silent nucleotide mutations in the particular CD46 constructs. This effect was consistent both for constructs encoding cell surface CD46 and constructs encoding soluble CD46. Other cell lines were tested for expression of wild-type and mutated constructs: mutation improved cell-surface CD46 protein expression in transiently transfected WOP-3027 cells, and in stably transfected CHO-Kl cells. Soluble protein was also produced with consistent and predictable expression in human 293 and 293-Ebna cells. Therefore, the effect of the mutation is not limited to COS-7 African Green monkey kidney fibroblast-like cells, but also is seen in WOP-3027 (polyoma virus-transformed) mouse embryonal fibroblast cells, CHO-Kl hamster ovary cells, and 293 (human embryonal kidney) cells. It is therefore likely that the effects will be observed in other cells also. To assess the effect of the vector upon the expression of mutated constructs, forms encoding soluble CD46 were cloned into the APEX-3 vector. Mutation-dependent enhanced expression was seen in COS-7 and 293 (human embryonal kidney) cells, demonstrating that the effect was not limited to one vector. Table II shows cell surface and soluble CD46 expression levels obtaining by transfection using a range of vectors, cell lines and constructs. The "±" symbol indicates basal, wild type expression levels and the number of "+" symbols shown for each test is directly proportional to the level of CD46 expression. EXAMPLE 4 Studies of translation rate in cell-free translation systems. CD46 synthetic wildtype and mutant transcripts were translated in vitro in a cell- free translation system containing rabbit reticulocytes (see Fig.10). The lanes containing equal quantities of RNA transcribed from wtSCR, subSCR2, subSCR3 and subSCR2+3 DNA sequences all produced a similar amount of protein, showing that translation proceeded with equivalent efficiency regardless of the sequence of the transcript. The protein was of the expected size for nonglycosylated CD46 (38-40kD). EXAMPLE 5 Enhanced expression of soluble CD46 in CHO-Kl, WOP-3027 and 293 cells. The soluble wtSCR and soluble subSCR3 constructs were transfected into WOP, CHO-Kl and 293 cells. An almost identical trend was observed when supernatants collected from transfected WOP cells were semi-quantitated by radioimmunoassay. Serum free supernatants from CHO cells collected 96 hours after transient transfection with soluble subSCR3, showed a 4-fold increase in protein expression (see Fig.l 1). This was consistent with the increase observed when a parental stable CHO cell line expressing surface CD46 was established after cotransfection with soluble subSCR2+3 and pgKNeopA. Serum free supernatants from 293 cells were collected 6 days after transfection, and semi-quantitated by dot blotting, more protein (typically 3-fold) was observed when the construct containing silent nucleotide changes (soluble subSCR3) was used. These data clearly show the increase in soluble CD46 protein produced after transfection with a mutated construct, was not restricted to COS-7 cells. EXAMPLE 6 Enhanced expression of soluble CD46 using APEX-3 expression plasmids Inserts encoding CD46 were ligated into the APEX- 3 expression plasmid, and the two constructs; APEX3-sol-wtSCR and APEX3-sol-subSCR3 transfected into COS-7 & 293 cells. Serum free supernatants were collected 6 days after transfection, and semiquantitated by dot blotting. An increase in protein expression (typicall 3-fold) was observed when cells were transfected with the construct containing silent nucleotide changes (APEX3-sol-subSCR3). The data confirm that the observed increase in protein expression was not plasmid specific. EXAMPLE 7 Studies to determine mechanism of enhanced protein expression. (a) Transiently transfected COS cells contain similar quantities of plasmid DNA whether transfected with CD46 constructs consisting of mutated (silent nucleotide substituted) or wildtype sequences, as measured by Southern blot analyses. Therefore, the significant increase in production of CD46 protein is most likely due to transcriptional or translational regulation, and not due to altered efficiency of transfection, DNA stability, or plasmid DNA replication. (b) COS cells transfected with mutated or wildtype CD46 plasmid constructs have equivalent quantities of CD46 mRNA but different quantities of CD46 protein. In two constructs (subSCR3 and subSCR2+3), a cryptic polyadenylation signal has been removed, which might have generated truncated mRNA species (in wildtype, delSCR2 or subSCR2 constructs). However, no truncated mRNA species are seen in Northern blots, and no differences in mRNA quantity, which might have been ascribed to altered mRNA stability or half-life, are observed. Therefore, the increased CD46 protein is most likely generated by regulation of translation. (c) In vitro translation, using as template equivalent amounts of mRNA isolated from each of the transfected COS cells, generates equivalent quantities of CD46 protein, whereas up to a 20-fold increase in cell-surface protein expression is reproducibly found in transfected COS cells. This focuses attention on the mechanism o protein translation, as it appears to be limited to specifically occurring within intact cells. (d) To determine whether the increase in CD46 production was due to protein COS-7 cells were separately transfected with wtSCR, subSCR2+3 or subSCR3, biosynthetically labelled with 35S-Cys and 35S-Met, and CD46 protein was immunoprecipitated from cell lysates and supernatants and examined by SDS- PAGE. Cells transfected with subSCR2+3 synthesised more labelled CD46 than than those transfected with wtSCR. There was no CD46 protein detectable in the supernatant. Biosynthetically labelled CD46 was produced by cells transfected with solSCR3 and was secreted into the supernatant but, as expected, could not be detected in the lysate. Lysates and supernatants immunoprecipitated with an isotype control mAb, MEM-43, did not show any labelled material of the expected size. EXAMPLE 8 The use of mutagenised CD46 and CD55 genes, encoding wildtype protein, for the production of transgenic animals. Once the optimised mutant construct, such as the CD46 encoding SCR2+3 construct (see above) or the appropriate CD 55 construct, has been proven by repeated transfection of eukaryotic cell lines in vitro, the DNA vector is highly purified to be suitable for transgenesis. The DNA (the transgene) is injected into fertilised mouse single-cell oocytes which are reimplanted into prepared pseudo-pregnant mice, entirely according to procedures familiar with those experienced in the art. The offspring are screened for integration of the transgene by Southern blotting DNA obtained from a small tissue sample, and founder mice are tested for transgene expression by Western blotting of a tissue cell lysate. Founders expressing the protein are bred and appropriately backcrossed to suitable mouse strains. Individual mice of each generation are also screened for protein expression of the transgene, and only expressing animals are used. Tissue samples from such transgenic mice are tested for function of the transgenic protein in complement-mediated lysis, complement-mediated graft rejection, and complement- mediated tissue inflammation assays, each of which is established and routine. Only animals expressing sufficient amounts of the CD46 or CD55 transgenic protein on their cells to have augmented resistance to complement-mediated cell damage are kept to establish transgenic strains of mice. are kept to establish transgenic strains of mice. Once function is confirmed using tissues of transgenic mice, which identifies the appropriate transgene DNA construct, the same transgenesis procedure is repeated using porcine oocytes, to produce transgenic pigs. The appropriate transgenic pigs are considered to be putative organ donors of xenogenic transplants for humans requiring kidney, heart, liver, pancreas, etc., grafts. An important application of the invention is the genetic cross between transgenic animals expressing CD46 with transgenic animals expressing CD55, where co-expressio of both molecules augments resistance to complement-mediated injury. Although the above example relates to production of transgenic animals to provid donors of organ implants, transgenic animals containing the constructs of the presen invention or whose cells produce proteins in accordance with the method of the invention may be produced for other purposes. For example it may be desired to produce transgenic cow which produces recombinant protein in its milk. It is to be recognised that the present invention has been described by way o example only and that modifications and/or alterations which would be obvious to person skilled in the art can be made thereto, without departing from the intended scop of the invention as defined in the appended claims. Table I. Oligonucleotides and the combinations used to generate mutated CD46 constructs. A. Oligonucleotide primers for PCR. PRIMER SEQUENCE 3 SIZE ANNEALING POSITION b On231 5 -CAATCΑGGTAσrAACCCTCGTTGCAσATσAAGTGCATC-3 ' 38-raer nt 436-399 On232 5 -cggaattcACAGCGTCTTCCGCGCCGCGC-3' 29-mer nt 4-32 On233 5 -GGTCTTGTGTACACCACCTCCAAAGATCAAGAATGGAAAAC-3 ' 41-mer nt 510-550 On238 5 -AGCAATGACC-TC^AACATCCAAACTGTC-3 ' 27-mer nt 1032-1006 On239 5 -TGGATGTTTAGGTCATTGCTGTGATT-3 ' 26-mer nt 1013-1038 On240 5 -GGTGTACACAAQACCTTATAACAGGCGTCATCTG-3 ' 34-πιer nt 524-509/319-302 tr. On241 5 -acgaattcGATTTCAAGCCACTTTCTTTACAAAG-3 ' 34-mer nt 1641-1608 On247 5 -GGTGGTGTACACAAGACCTTCrCACATATTGG-3 ' 32-mer nt 527-496 IΛ On250 5 -CGAGGGTTACTACCTGATTGGTGAGGASATCCTOTATTGTGAAC- 44-mer nt 417-460 a EcoRl restriction sites and overhang are shown in lower case; mutated nucleotides are in italics and bold font. b Annealing position is based on pm5.1 (Purcell et al., 1991) CO B M H B. Primer combinations for mutated CD46 constructs produced by PCR. MUTATED 5' PCR 3' PCR CONSTRUCT FRAGMENT FRAGMENT TEMPLATE subSCR2 On232 / On231 On241 / On250 pm5.1 subSCR3 0n232 / On247 On241 / On233 pm5.1 subSCR2+3 On232 / On231 On241 / On250 subSCR3 delSCR2/subSCR3 On232 / On240 On241 / On2 7 pm5.1 sol- tSCR On232 / On238 On241 / On239 pm5.1 sol-subSCR3 On232 / On247 On241 / On233 sol-wtSCR Table II Cell surface and soluble CD46 expression obtained by transfection of constructs into various cell lines Ccll-surfacc CD46 Construe 1 Soluble - CD46 Construct wild¬ sub2 sub3 sub del2 wild- sub3 sub del2 1.8 type 2+3 sub3 type 2+3 sub3 mutant pcDNAl vector COS-7 + + + +++ ++ + + + +++ + + + + + + ++ + ++ 293 ± + + + 293-Ebna ± + + + WOP- 3027 + +++ ± +-+ + CHO-Kl + + ++ + ++ + ++ APEX-3 vector COS-7 + ++ + + 293 ± + + + + SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: AUSTIN RESEARCH INSTITUTE (ii) TITLE OF INVENTION: IMPROVEMENTS IN PRODUCTION OF PROTEINS IN HOST CELLS (iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: DA VIES COLLISON CAVE (B) STREET: LEVEL 10, 10 BARRACK STREET (C) CITY: SYDNEY (D) STATE: NSW (E) COUNTRY: AUSTRALIA (F) ZIP: 2000 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Dr Peter A Stearne (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: +612 262 2611 (B) TELEFAX: +612 262 1080 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1 134 (xi) SEQUENCE DESCRIPTION: wtSCR ATG GAG CCT CCC GGC CGC CGC GAG TGT CCC TTT CCT TCC TGG CGC TT 4 Met Glu Pro Pro Gly Arg Arg Glu Cys Pro Phe Pro Ser Trp Arg Phe 1 5 10 15 CCT GGG TTG CTT CTG GCG GCC ATG GTG TTG CTG CTG TAC TCC TTC TCC 9 Pro Gly Leu Leu Leu Ala Ala Met Val Leu Leu Leu Tyr Ser Phe Ser 20 25 30 GAT GCC TGT GAG GAG CCA CCA ACA TT GAA GCT ATG GAG CTC ATT GGT 144 Asp Ala Cys Glu Glu Pro Pro Thr Phe Glu Ala Met Glu Leu He Gly 35 40 45 AAA CCA AAA CCC TAC TAT GAG ATT GGT GAA CGA GTA GAT TAT AAG TGT 19 Lys Pro Lys Pro Tyr Tyr Glu He Gly Glu Arg Val Asp Tyr Lys Cys 50 55 60 AAA AAA GGA TAC TC TAT ATA CCT CCT CTT GCC ACC CAT ACT ATT TGT 24 Lys Lys Gly Tyr Phe Tyr He Pro Pro Leu Ala Thr His Thr He Cys 65 70 75 80 GAT CGG AAT CAT ACA TGG CTA CCT GTC TCA GAT GAC GCC TGT TAT AGA 28 Asp Arg Asn His Thr Trp Leu Pro Val Ser Asp Asp Ala Cys Tyr Arg 85 90 95 GAA ACA TGT CCA TAT ATA CGG GAT CCT TTA AAT GGC CAA GCA GTC CCT 33 Glu Thr Cys Pro Tyr He Arg Asp Pro Leu Asn Gly Gin Ala Val Pro 100 105 110 GCA AAT GGG ACT TAC GAG TTT GGT TAT CAG ATG CAC TTT ATT TGT AAT 38 Ala Asn Gly Thr Tyr Glu Phe Gly Tyr Gin Met His Phe He Cys Asn 115 120 125 GAG GGT TAT TAC TTA ATT GGT GAA GAA ATT CTA TAT TGT GAA CTT AAA 43 Glu Gly Tyr Tyr Leu He Gly Glu Glu He Leu Tyr Cys Glu Leu Lys 130 135 140 GGA TCA GTA GCA ATT TGG AGC GGT AAG CCC CCA ATA TGT GAA AAG GTT 48 Gly Ser Val Ala He Trp Ser Gly Lys Pro Pro He Cys Glu Lys Val 145 150 155 160 TTG TGT ACA CCA CCT CCA AAA ATA AAA AAT GGA AAA CAC ACC TTT AGT 528 Leu Cys Thr Pro Pro Pro Lys He Lys Asn Gly Lys His Thr Phe Ser 165 170 175 GAA GTA GAA GTA TTT GAG TAT CTT GAT GCA GTA ACT TAT AGT TGT GAT 576 Glu Val Glu Val Phe Glu Tyr Leu Asp Ala Val Thr Tyr Ser Cys Asp 180 185 190 CCT GCA CCT GGA CCA GAT CCA TTT TCA CTT ATT GGA GAG AGC ACG ATT 624 Pro Ala Pro Gly Pro Asp Pro Phe Ser Leu He Gly Glu Ser Thr He 195 200 205 TAT TGT GGT GAC AAT TCA GTG TGG AGT CGT GCT GCT CCA GAG TGT AAA 672 Tyr Cys Gly Asp Asn Ser Val Trp Ser Arg Ala Ala Pro Glu Cys Lys 210 215 220 GTG GTC AAA TGT CGA TTT CCA GTA GTC GAA AAT GGA AAA CAG ATA TCA 720 Val Val Lys Cys Arg Phe Pro Val Val Glu Asn Gly Lys Gin He Ser 225 230 235 240 GGA TTT GGA AAA AAA TTT TAC TAC AAA GCA ACA GTT ATG TTT GAA TGC 768 Gly Phe Gly Lys Lys Phe Tyr Tyr Lys Ala Thr Val Met Phe Glu Cys 245 250 255 GAT AAG GGT TTT TAC CTC GAT GGC AGC GAC ACA ATT GTC TGT GAC AGT 816 Asp. Lys Gly Phe Tyr Leu Asp Gly Ser Asp Thr He Val Cys Asp Ser 260 265 270 AAC AGT ACT TGG GAT CCC CCA GTT CCA AAG TGT CTT AAA GTG TCG ACT 864 Asn Ser Thr Trp Asp Pro Pro Val Pro Lys Cys Leu Lys Val Ser Thr 275 280 285 TCT TCC ACT ACA AAA TCT CCA GCG TCC AGT GCC TCA GGT CCT AGG CCT 912 Ser Ser Thr Thr Lys Ser Pro Ala Ser Ser Ala Ser Gly Pro Arg Pro 290 295 300 ACT TAC AAG CCT CCA GTC TCA AAT TAT CCA GGA TAT CCT AAA CCT GAG 960 Thr Tyr Lys Pro Pro Val Ser Asn Tyr Pro Gly Tyr Pro Lys Pro Glu 305 310 315 320 GAA GGA ATA CTT GAC AGT TTG GAT GTT TGG GTC ATT GCT GTG ATT GTT 1008 Glu Gly He Leu Asp Ser Leu Asp Val Trp Val He Ala Val He Val 325 330 335 ATT GCC ATA GTT GTT GGA GTT GCA GTA ATT TGT GTT GTC CCG TAC AGA 1056 He Ala He Val Val Gly Val Ala Val He Cys Val Val Pro Tyr Arg 340 345 350 TAT CTT CAA AGG AGG AAG AAG AAA GGC ACA TAC CTA ACT GAT GAG ACC 1104 Tyr Leu Gin Arg Arg Lys Lys Lys Gly Thr Tyr Leu Thr Asp Glu Thr 355 360 365 CAC AGA GAA GTA AAA TTT ACT TCT CTC TGA 1134 His Arg Glu Val Lys Phe Thr Ser Leu * 370 375 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA 10 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1 134 15 (xi) SEQUENCE DESCRIPTION: subSRCR2 ATG GAG CCT CCC GGC CGC CGC GAG TGT CCC TTT CCT TCC TGG CGC TTT 48 20 Met Glu Pro Pro Gly Arg Arg Glu Cys Pro Phe Pro Ser Trp Arg Phe 1 5 10 15 CCT GGG TTG CTT CTG GCG GCC ATG GTG TTG CTG CTG TAC TCC TTC TCC 96 Pro Gly Leu Leu Leu Ala Ala Met Val Leu Leu Leu Tyr Ser Phe Ser 25 20 25 30 GAT GCC TGT GAG GAG CCA CCA ACA TTT GAA GCT ATG GAG CTC ATT GGT 144 Leu He Gly AAA CCA AAA CCC TAC TAT GAG ATT GGT GAA CGA GTA GAT TAT AAG TGT 192 Lys Pro Lys Pro Tyr Tyr Glu He Gly Glu Arg Val Asp Tyr Lys Cys 50 55 60 35 AAA AAA GGA TAC TTC TAT ATA CCT CCT CTT GCC ACC CAT ACT ATT TGT 240 Lys Lys Gly Tyr Phe Tyr He Pro Pro Leu Ala Thr His Thr He Cys 65 70 75 80 GAT CGG AAT CAT ACA TGG CTA CCT GTC TCA GAT GAC GCC TGT TAT AGA 288 40 Asp Arg Asn His Thr Trp Leu Pro Val Ser Asp Asp Ala Cys Tyr Arg 85 90 95 GAA ACA TGT CCA TAT ATA CGG GAT CCT TTA AAT GGC CAA GCA GTC CCT 336 Glu Thr Cys Pro Tyr He Arg Asp Pro Leu Asn Gly Gin Ala Val Pro 45 100 105 110 GCA AAT GGG ACT TAC GAG TT GGT TAT CAG ATG CAC TCT ACT TGC AAC 384 Ala Asn Gly Thr Tyr Glu Phe Gly Tyr Gin Met His Ser Thr Cys Asn 115 120 125 50 GAG GGT TAC TAC CTG ATT GGT GAG GAG ATC CTG TAT TGT GAA CTT AAA 432 Glu Gly Tyr Tyr Leu He Gly Glu Glu He Leu Tyr Cys Glu Leu Lys 130 135 140 55 GGA TCA GTA GCA ATT TGG AGC GGT AAG CCC CCA ATA TGT GAA AAG GTT 480 Gly Ser Val Ala He Trp Ser Gly Lys Pro Pro He Cys Glu Lys Val 145 150 155 160 TTG TGT ACA CCA CCT CCA AAA ATA AAA AAT GGA AAA CAC ACC TTT AGT 528 Leu Cys Thr Pro Pro Pro Lys He Lys Asn Gly Lys His Thr Phe Ser 165 170 175 GAA GTA GAA GTA TTT GAG TAT CTT GAT GCA GTA ACT TAT AGT TGT GAT 576 Glu Val Glu Val Phe Glu Tyr Leu Asp Ala Val Thr Tyr Ser Cys Asp 180 185 190 CCT GCA CCT GGA CCA GAT CCA TTT TCA CTT ATT GGA GAG AGC ACG ATT 624 Pro Ala Pro Gly Pro Asp Pro Phe Ser Leu He Gly Glu Ser Thr He 195 200 205 TAT TGT GGT GAC AAT TCA GTG TGG AGT CGT GCT GCT CCA GAG TGT AAA 672 Tyr Cys Gly Asp Asn Ser Val Trp Ser Arg Ala Ala Pro Glu Cys Lys 210 215 220 GTG GTC AAA TGT CGA TTT CCA GTA GTC GAA AAT GGA AAA CAG ATA TCA 720 Val Val Lys Cys Arg Phe Pro Val Val Glu Asn Gly Lys Gin He Ser 225 230 235 240 GGA TTT GGA AAA AAA TTT TAC TAC AAA GCA ACA GTT ATG TTT GAA TGC 768 Gly Phe Gly Lys Lys Phe Tyr Tyr Lys Ala Thr Val Met Phe Glu Cys 245 250 255 GAT AAG GGT TTT TAC CTC GAT GGC AGC GAC ACA ATT GTC TGT GAC AGT 816 Asp Lys Gly Phe Tyr Leu Asp Gly Ser Asp Thr He Val Cys Asp Ser 260 265 270 AAC AGT ACT TGG GAT CCC CCA GTT CCA AAG TGT CTT AAA GTG TCG ACT 864 Asn Ser Thr Trp Asp Pro Pro Val Pro Lys Cys Leu Lys Val Ser Thr 275 280 285 TCT TCC ACT ACA AAA TCT CCA GCG TCC AGT GCC TCA GGT CCT AGG CCT 912 Ser Ser Thr Thr Lys Ser Pro Ala Ser Ser Ala Ser Gly Pro Arg Pro 290 295 300 ACT TAC AAG CCT CCA GTC TCA AAT TAT CCA GGA TAT CCT AAA CCT GAG 960 Thr Tyr Lys Pro Pro Val Ser Asn Tyr Pro Gly Tyr Pro Lys Pro Glu 305 310 315 320 GAA GGA ATA CTT GAC AGT TTG GAT GTT TGG GTC ATT GCT GTG ATT GTT 1008 Glu Gly He Leu Asp Ser Leu Asp Val Trp Val He Ala Val He Val 325 330 335 ATT GCC ATA GTT GTT GGA GTT GCA GTA ATT TGT GTT GTC CCG TAC AGA 1056 He Ala He Val Val Gly Val Ala Val He Cys Val Val Pro Tyr Arg 340 345 350 TAT CTT CAA AGG AGG AAG AAG AAA GGC ACA TAC CTA ACT GAT GAG ACC 1104 Tyr Leu Gin Arg Arg Lys Lys Lys Gly Thr Tyr Leu Thr Asp Glu Thr 355 360 365 CAC AGA GAA GTA AAA TTT ACT TCT CTC TGA 1134 His Arg Glu Val Lys Phe Thr Ser Leu * 370 375 (2) INFORMATION FOR SEQ ID NO:3: (0 SEQUENCE CHARACTERISTICS: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1134 (xi) SEQUENCE DESCRIPTION: subSCR3 ATG GAG CCT CCC GGC CGC CGC GAG TGT CCC TTT CCT TCC TGG CGC TTT 4 Met Glu Pro Pro Gly Arg Arg Glu Cys Pro Phe Pro Ser Trp Arg Phe 1 5 10 15 CCT GGG TTG CTT CTG GCG GCC ATG GTG TTG CTG CTG TAC TCC TTC TCC 9 Pro Gly Leu Leu Leu Ala Ala Met Val Leu Leu Leu Tyr Ser Phe Ser 20 25 30 GAT GCC TGT GAG GAG CCA CCA ACA TTT GAA GCT ATG GAG CTC ATT GGT 14 Asp Ala Cys Glu Glu Pro Pro Thr Phe Glu Ala Met Glu Leu He Gly 35 40 45 AAA CCA AAA CCC TAC TAT GAG ATT GGT GAA CGA GTA GAT TAT AAG TGT 19 Lys Pro Lys Pro Tyr Tyr Glu He Gly Glu Arg Val Asp Tyr Lys Cys 50 55 60 AAA AAA GGA TAC TTC TAT ATA CCT CCT CTT GCC ACC CAT ACT ATT TGT 24 Lys Lys Gly Tyr Phe Tyr He Pro Pro Leu Ala Thr His Thr He Cys 65 70 75 80 GAT CGG AAT CAT ACA TGG CTA CCT GTC TCA GAT GAC GCC TGT TAT AGA 28 Asp Arg Asn His Thr Trp Leu Pro Val Ser Asp Asp Ala Cys Tyr Arg 85 90 95 GAA ACA TGT CCA TAT ATA CGG GAT CCT TTA AAT GGC CAA GCA GTC CCT 33 Glu Thr Cys Pro Tyr He Arg Asp Pro Leu Asn Gly Gin Ala Val Pro 100 105 110 GCA AAT GGG ACT TAC GAG TTT GGT TAT CAG ATG CAC TTT ATT TGT AAT 38 Ala Asn Gly Thr Tyr Glu Phe Gly Tyr Gin Met His Phe He Cys Asn 115 120 125 GAG GGT TAT TAC TTA ATT GGT GAA GAA ATT CTA TAT TGT GAA CTT AAA 43 Glu Gly Tyr Tyr Leu He Gly Glu Glu He Leu Tyr Cys Glu Leu Lys 130 135 140 GGA TCA GTA GCA ATT TGG AGC GGT AAG CCC CCA ATA TGT GAG AAG GTC 48 Gly Ser Val Ala He Trp Ser Gly Lys Pro Pro He Cys Glu Lys Val 145 150 155 160 TTG TGT ACA CCA CCT CCA AAG ATC AAG AAT GGA AAA CAC ACC TTT AGT 528 Leu Cys Thr Pro Pro Pro Lys He Lys Asn Gly Lys His Thr Phe Ser 165 170 175 GAA GTA GAA GTA TTT GAG TAT CTT GAT GCA GTA ACT TAT AGT TGT GAT 576 Glu Val Glu Val Phe Glu Tyr Leu Asp Ala Val Thr Tyr Ser Cys Asp 180 185 190 CCT GCA CCT GGA CCA GAT CCA TTT TCA CTT ATT GGA GAG AGC ACG ATT 624 Pro Ala Pro Gly Pro Asp Pro Phe Ser Leu He Gly Glu Ser Thr He 195 200 205 TAT TGT GGT GAC AAT TCA GTG TGG AGT CGT GCT GCT CCA GAG TGT AAA 672 Tyr Cys Gly Asp Asn Ser Val Trp Ser Arg Ala Ala Pro Glu Cys Lys 210 215 220 GTG GTC AAA TGT CGA TTT CCA GTA GTC GAA AAT GGA AAA CAG ATA TCA 720 Val Val Lys Cys Arg Phe Pro Val Val Glu Asn Gly Lys Gin He Ser 225 230 235 240 GGA TTT GGA AAA AAA TTT TAC TAC AAA GCA ACA GTT ATG TTT GAA TGC 768 Gly Phe Gly Lys Lys Phe Tyr Tyr Lys Ala Thr Val Met Phe Glu Cys 245 250 255 GAT AAG GGT TTT TAC CTC GAT GGC AGC GAC ACA ATT GTC TGT GAC AGT 816 Asp Lys Gly Phe Tyr Leu Asp Gly Ser Asp Thr He Val Cys Asp Ser 260 265 270 AAC AGT ACT TGG GAT CCC CCA GTT CCA AAG TGT CTT AAA GTG TCG ACT 864 Asn Ser Thr Trp Asp Pro Pro Val Pro Lys Cys Leu Lys Val Ser Thr 275 280 285 TCT TCC ACT ACA AAA TCT CCA GCG TCC AGT GCC TCA GGT CCT AGG CCT 912 Ser Ser Thr Thr Lys Ser Pro Ala Ser Ser Ala Ser Gly Pro Arg Pro 290 295 300 ACT TAC AAG CCT CCA GTC TCA AAT TAT CCA GGA TAT CCT AAA CCT GAG 960 Thr Tyr Lys Pro Pro Val Ser Asn Tyr Pro Gly Tyr Pro Lys Pro Glu 305 310 315 320 GAA GGA ATA CTT GAC AGT TTG GAT GTT TGG GTC ATT GCT GTG ATT GTT 1008 Glu Gly He Leu Asp Ser Leu Asp Val Trp Val He Ala Val He Val 325 330 335 ATT GCC ATA GTT GTT GGA GTT GCA GTA ATT TGT GTT GTC CCG TAC AGA 1056 He Ala He Val Val Gly Val Ala Val He Cys Val Val Pro Tyr Arg 340 345 350 TAT CTT CAA AGG AGG AAG AAG AAA GGC ACA TAC CTA ACT GAT GAG ACC 1104 Tyr Leu Gin Arg Arg Lys Lys Lys Gly Thr Tyr Leu Thr Asp Glu Thr 355 360 365 CAC AGA GAA GTA AAA TTT ACT TCT CTC TGA 1134 His Arg Glu Val Lys Phe Thr Ser Leu * 370 375 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1134 (xi) SEQUENCE DESCRIPTION: subSCR2+3 ATG GAG CCT CCC GGC CGC CGC GAG TGT CCC TTT CCT TCC TGG CGC TTT 4 Met Glu Pro Pro Gly Arg Arg Glu Cys Pro Phe Pro Ser Trp Arg Phe 1 5 10 15 CCT GGG TTG CTT CTG GCG GCC ATG GTG TTG CTG CTG TAC TCC TTC TCC 9 Pro Gly Leu Leu Leu Ala Ala Met Val Leu Leu Leu Tyr Ser Phe Ser 20 25 30 GAT GCC TGT GAG GAG CCA CCA ACA TTT GAA GCT ATG GAG CTC ATT GGT 14 Asp Ala Cys Glu Glu Pro Pro Thr Phe Glu Ala Met Glu Leu He Gly 35 40 45 AAA CCA AAA CCC TAC TAT GAG ATT GGT GAA CGA GTA GAT TAT AAG TGT 19 Lys Pro Lys Pro Tyr Tyr Glu He Gly Glu Arg Val Asp Tyr Lys Cys 50 55 60 AAA AAA GGA TAC TTC TAT ATA CCT CCT CTT GCC ACC CAT ACT ATT TGT 24 Lys Lys Gly Tyr Phe Tyr He Pro Pro Leu Ala Thr His Thr He Cys 65 70 75 80 GAT CGG AAT CAT ACA TGG CTA CCT GTC TCA GAT GAC GCC TGT TAT AGA 28 Asp Arg Asn His Thr Trp Leu Pro Val Ser Asp Asp Ala Cys Tyr Arg 85 90 95 GAA ACA TGT CCA TAT ATA CGG GAT CCT TTA AAT GGC CAA GCA GTC CCT 33 Glu Thr Cys Pro Tyr He Arg Asp Pro Leu Asn Gly Gin Ala Val Pro 100 105 110 GCA AAT GGG ACT TAC GAG TTT GGT TAT CAG ATG CAC CT ACT TGC AAC 38 Ala Asn Gly Thr Tyr Glu Phe Gly Tyr Gin Met His Ser Thr Cys Asn 115 120 125 GAG GGT TAC TAC CTG ATT GGT GAG GAG ATC CTG TAT TGT GAA CTT AAA 43 Glu Gly Tyr Tyr Leu He Gly Glu Glu He Leu Tyr Cys Glu Leu Lys 130 135 140 GGA TCA GTA GCA ATT TGG AGC GGT AAG CCC CCA ATA TGT GAG AAG GTC 48 Gly Ser Val Ala He Trp Ser Gly Lys Pro Pro He Cys Glu Lys Val 145 150 155 160 TTG TGT ACA CCA CCT CCA AAG ATC AAG AAT GGA AAA CAC ACC TTT AGT 528 Leu Cys Thr Pro Pro Pro Lys He Lys Asn Gly Lys His Thr Phe Ser 165 170 175 GAA GTA GAA GTA TTT GAG TAT CTT GAT GCA GTA ACT TAT AGT TGT GAT 576 Glu Val Glu Val Phe Glu Tyr Leu Asp Ala Val Thr Tyr Ser Cys Asp 180 185 190 CCT GCA CCT GGA CCA GAT CCA TTT TCA CTT ATT GGA GAG AGC ACG ATT 624 Pro Ala Pro Gly Pro Asp Pro Phe Ser Leu He Gly Glu Ser Thr He 195 200 205 TAT TGT GGT GAC AAT TCA GTG TGG AGT CGT GCT GCT CCA GAG TGT AAA 672 Tyr Cys Gly Asp Asn Ser Val Trp Ser Arg Ala Ala Pro Glu Cys Lys 210 215 220 GTG GTC AAA TGT CGA TTT CCA GTA GTC GAA AAT GGA AAA CAG ATA TCA 720 Val Val Lys Cys Arg Phe Pro Val Val Glu Asn Gly Lys Gin He Ser 225 230 235 240 GGA TTT GGA AAA AAA TTT TAC TAC AAA GCA ACA GTT ATG TTT GAA TGC 768 Gly Phe Gly Lys Lys Phe Tyr Tyr Lys Ala Thr Val Met Phe Glu Cys 245 250 255 GAT AAG GGT TTT TAC CTC GAT GGC AGC GAC ACA ATT GTC TGT GAC AGT 816 Asp Lys Gly Phe Tyr Leu Asp Gly Ser Asp Thr He Val Cys Asp Ser 260 265 270 AAC AGT ACT TGG GAT CCC CCA GTT CCA AAG TGT CTT AAA GTG TCG ACT 864 Asn Ser Thr Trp Asp Pro Pro Val Pro Lys Cys Leu Lys Val Ser Thr 275 280 285 TCT TCC ACT ACA AAA TCT CCA GCG TCC AGT GCC TCA GGT CCT AGG CCT 912 Ser Ser Thr Thr Lys Ser Pro Ala Ser Ser Ala Ser Gly Pro Arg Pro 290 295 300 ACT TAC AAG CCT CCA GTC TCA AAT TAT CCA GGA TAT CCT AAA CCT GAG 960 Thr Tyr Lys Pro Pro Val Ser Asn Tyr Pro Gly Tyr Pro Lys Pro Glu 305 310 315 320 GAA GGA ATA CTT GAC AGT TTG GAT GTT TGG GTC ATT GCT GTG ATT GTT 1008 Glu Gly He Leu Asp Ser Leu Asp Val Trp Val He Ala Val He Val 325 330 335 ATT GCC ATA GTT GTT GGA GTT GCA GTA ATT TGT GTT GTC CCG TAC AGA 1056 He Ala He Val Val Gly Val Ala Val He Cys Val Val Pro Tyr Arg 340 345 350 TAT CTT CAA AGG AGG AAG AAG AAA GGC ACA TAC CTA ACT GAT GAG ACC 1104 Tyr Leu Gin Arg Arg Lys Lys Lys Gly Thr Tyr Leu Thr Asp Glu Thr 355 360 365 CAC AGA GAA GTA AAA TTT ACT TCT CTC TGA 1134 His Arg Glu Val Lys Phe Thr Ser Leu * 370 375 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA 10 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1 .1134 15 (xi) SEQUENCE DESCRIPTION: delSCR2/subSCR3 ATG GAG CCT CCC GGC CGC CGC GAG TGT CCC TTT CCT TCC TGG CGC TTT 4 20 Met Glu Pro Pro Gly Arg Arg Glu Cys Pro Phe Pro Ser Trp Arg Phe 1 5 10 15 CCT GGG TTG CTT CTG GCG GCC ATG GTG TTG CTG CTG TAC TCC TTC TCC 9 Pro Gly Leu Leu Leu Ala Ala Met Val Leu Leu Leu Tyr Ser Phe Ser 25 20 25 30 GAT GCC TGT GAG GAG CCA CCA ACA TTT GAA GCT ATG GAG CTC ATT GGT 14 Leu He Gly Jiυn AAA CCA AAA CCC TAC TAT GAG ATT GGT GAA CGA GTA GAT TAT AAG TGT 19 Lys Pro Lys Pro Tyr Tyr Glu He Gly Glu Arg Val Asp Tyr Lys Cys 50 55 60 35 AAA AAA GGA TAC TC TAT ATA CCT CCT CTT GCC ACC CAT ACT ATT TGT 24 Lys Lys Gly Tyr Phe Tyr He Pro Pro Leu Ala Thr His Thr He Cys 65 70 75 80 GAT CGG AAT CAT ACA TGG CTA CCT GTC TCA GAT GAC GCC TGT TAT AGG 28 40 Asp Arg Asn His Thr Trp Leu Pro Val Ser Asp Asp Ala Cys Tyr Arg 85 90 95 GTC TTG TGT ACA CCA CCT CCA AAG ATC AAG AAT GGA AAA CAC ACC TTT 33 Val Leu Cys Thr Pro Pro Pro Lys He Lys Asn Gly Lys His Thr Phe 45 100 105 110 AGT GAA GTA GAA GTA TTT GAG TAT CTT GAT GCA GTA ACT TAT AGT TGT 38 Ser Glu Val Glu Val Phe Glu Tyr Leu Asp Ala Val Thr Tyr Ser Cys 115 120 125 50 GAT CCT GCA CCT GGA CCA GAT CCA TTT TCA CTT ATT GGA GAG AGC ACG 43 Asp Pro Ala Pro Gly Pro Asp Pro Phe Ser Leu He Gly Glu Ser Thr 130 135 140 55 ATT TAT TGT GGT GAC AAT TCA GTG TGG AGT CGT GCT GCT CCA GAG TGT 48 He Tyr Cys Gly Asp Asn Ser Val Trp Ser Arg Ala Ala Pro Glu Cys 145 150 155 160 AAA GTG GTC AAA TGT CGA TTT CCA GTA GTC GAA AAT GGA AAA CAG ATA 528 Lys Val Val Lys Cys Arg Phe Pro Val Val Glu Asn Gly Lys Gin He 165 170 175 TCA GGA TTT GGA AAA AAA TTT TAC TAC AAA GCA ACA GTT ATG TTT GAA 576 Ser Gly Phe Gly Lys Lys Phe Tyr Tyr Lys Ala Thr Val Met Phe Glu 180 185 190 TGC GAT AAG GGT TTT TAC CTC GAT GGC AGC GAC ACA ATT GTC TGT GAC 624 Cys Asp Lys Gly Phe Tyr Leu Asp Gly Ser Asp Thr He Val Cys Asp 195 200 205 AGT AAC AGT ACT TGG GAT CCC CCA GTT CCA AAG TGT CTT AAA GTG TCG 672 Ser Asn Ser Thr Trp Asp Pro Pro Val Pro Lys Cys Leu Lys Val Ser 210 215 220 ACT TCT TCC ACT ACA AAA TCT CCA GCG TCC AGT GCC TCA GGT CCT AGG 720 Thr Ser Ser Thr Thr Lys Ser Pro Ala Ser Ser Ala Ser Gly Pro Arg 225 230 235 240 CCT ACT TAC AAG CCT CCA GTC TCA AAT TAT CCA GGA TAT CCT AAA CCT 768 Pro Thr Tyr Lys Pro Pro Val Ser Asn Tyr Pro Gly Tyr Pro Lys Pro 245 250 255 GAG GAA GGA ATA CTT GAC AGT TTG GAT GTT TGG GTC ATT GCT GTG ATT 816 Glu Glu Gly He Leu Asp Ser Leu Asp Val Trp Val He Ala Val He 260 265 270 GTT ATT GCC ATA GTT GTT GGA GTT GCA GTA ATT TGT GTT GTC CCG TAC 864 Val He Ala He Val Val Gly Val Ala Val He Cys Val Val Pro Tyr 275 280 285 AGA TAT CTT CAA AGG AGG AAG AAG AAA GGC ACA TAC CTA ACT GAT GAG 912 Arg Tyr Leu Gin Arg Arg Lys Lys Lys Gly Thr Tyr Leu Thr Asp Glu 290 295 300 ACC CAC AGA GAA GTA AAA TTT ACT TCT CTC TGA 945 Thr His Arg Glu Val Lys Phe Thr Ser Leu * 305 310 315

Claims: THE CLAIMS 1. A method of increasing or improving protein production in a host cell where nucleic acid encoding the protein has an A and/or T rich region present in an exon, sai method comprising altering the nucleic acid by reducing or lowering the amount of and/or T in said region and transfecting a host cell with said altered nucleic acid and under appropriate conditions, obtaining expression of said nucleic acid. 2. The method of claim 1 wherein said altered nucleic acid is transfected into sai host cell as a component of a recombinant nucleic acid construct. 3. The method of either claim 1 or claim 2 wherein said altering of the nucleic aci is by effecting one or more silent mutations. 4. The method of either claim 1 or claim 2 wherein said altering of the nucleic aci is by effecting one or more conservative mutations. 5. The method of either claim 1 or claim 2 wherein said altering of the nucleic aci is by insertion of one or more nucleotides other than A or T. 6. The method of either claim 1 or claim 2 wherein said altering of the nucleic aci is by deletion of A and/or T or deletion of A and/or T rich regions. 7. The method of either claim 1 or claim 2 wherein said altering of the nucleic aci is by a combination of any two or more of a. one or more silent mutations b. one or more conservative mutations c. insertion of one or more nucleotides other than A or T d. deletion of A and/or T or deletion of A and/or T rich regions. 8. The method of any one of claims 1 to 7 wherein said nucleic acid is a nucleic aci encoding an RCA protein which has A and/or T rich regions present in one or more o its SCR modules. 9. The method of claim 8 wherein said nucleic acid is altered in one or more of its SCR modules. 10. The method of claim 9 when dependent upon claim 6, wherein said altering of the nucleic acid is by deletion of one or more SCR modules or parts thereof. 1 1. The method of any one of claims 8 to 10 wherein said RCA protein is CD46. 12. The method of claim 1 1 which utilises one of constructs subSCR2, subSCR3, subSCR2+3 or delSCR/subSCR3. 13. The method of any one of claims 3 to 12 when dependent upon claim 2 wherein said recombinant nucleic acid construct includes an eukaryotic vector. 14. The method of any one of claims 1 to 13 wherein said host cell is an eukaryotic host cell. 15. The method of claim 14 wherein said host cell is COS-7 or CHO-Kl. 16. A recombinant nucleic acid construct which is capable of increased production of a protein in a host cell wherein the amount of A and/or T in one or more A and/or T rich region present in one or more exons of the nucleic acid construct has been reduced. 17. The recombinant nucleic acid construct according to claim 16 which encodes an altered RCA cDNA sequence. 18. The recombinant nucleic acid construct according to claim 17 which encodes an altered CD46 cDNA sequence. 19. Recombinant nucleic acid constructs subSCR2, subSCR3, subSCR +3 and delSCR2/subSCR3. 20. Method of generating a transgenic animal by incorporating constructs according to any one of claims 16 to 19 or their derivatives into genetic information of the animal. 21. Method of producing a transgenic animal whose organs produce cell surface CD46 by incorporating constructs according to either claim 18 or claim 19 or their derivatives into genetic information of the animal. 22. The method of claim 21 wherein said animal is a pig. 23. A method of organ transplantation into humans or animals utilising organs of the transgenic animals produced according to the methods of either claim 21 or claim 22. 24. Purified protein preparations produced by the method of any one of claims 1 to 15. 25. Purified protein preparations produced by the nucleic acid constructs according to any one of claims 16 to 19. 26. Pharmaceutical compositions comprising a purified protein preparation according to either claim 24 or 25 in association with one or more pharmaceutically appropriate carrier or diluent. 27. Method of (a) treatment of complement medicated or inflammation medicated tissue damage; (b) enhancing immunity to tumors or viruses; (c) control of fertilization; or (d) prevention of spontaneous abortion in a human or animal which comprises administering an effective amount of a purified protein according to either claim 24 or 25 optionally in association with one or more pharmaceutically appropriate carrier or diluent.

Inventors: CHRISTIANSEN DALE, LOVELAND BRUCE, MCKENZIE IAN F C, MILLAND JULIE, CHRISTIANSEN, DALE, LOVELAND, BRUCE, MCKENZIE, IAN, F., C., MILLAND, JULIE
Applicants: AUSTIN RESEARCH INST, CHRISTIANSEN DALE, LOVELAND BRUCE, MCKENZIE IAN F C, MILLAND JULIE, CHRISTIANSEN, DALE, LOVELAND, BRUCE, MCKENZIE, IAN, F., C., MILLAND, JULIE, THE AUSTIN RESEARCH INSTITUTE
Application year: 1995
Main classification: C12N15
IPC codes: A01K67, A61K35, A61K38, A61K48, A61P13, A61P15, A61P29, A61P31, A61P35, A61P43, C07K14, C12N5, C12N15, C12P21, C12R1